FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2023653902> ?p ?o ?g. }

• W2023653902 endingPage "S125" @default.
• W2023653902 startingPage "S122" @default.
• W2023653902 abstract "BackgroundThe pathogenic role of hyperlipidemia in long-standing nephrotic syndrome (NS) is known to be responsible for both the progression of glomerulosclerosis and tubulointerstitial injury, especially in focal segmental glomerulosclerosis (FGS).MethodsAggressive lipid lowering treatment by low density lipoprotein (LDL) apheresis (LDL-A) using a dextran sulfate cellulose column to treat patients with steroid-resistant or frequently recurrent severe NS was performed first without fixing the protocol in eight patients with FGS and one with minimal change nephrotic syndrome (MCNS). The period of NS before LDL-A, number and average intervals of LDL-A until the end of the therapy, and the prognosis were investigated. Next, a multicenter study with a fixed protocol of LDL-A treatment was designed in combination with steroid therapy for treatment twice a week for three weeks and weekly for six weeks, and was performed in 17 patients with FGS. The effects on the state of NS in addition to the change of urinary eicosanoid metabolites and remission rates were evaluated.ResultsIn the preliminary study, along with a rapid improvement of hyperlipidemia, a high incidence of remission was achieved by LDL-A performed at relatively short intervals. In the multicenter study with a fixed protocol, there was a significant decrease of urinary protein (P < 0.001) and increase of serum albumin (P < 0.02) as well as a decrease of thromboxane B2 (TXB2) excretion (P < 0.05) after the treatment. Urinary excretion of TXB2 was significantly reduced after LDL-A (P < 0.05). The rate of entering into complete or incomplete remission was 71% with a relatively short duration of nephrotic-range proteinuria using the LDL-A therapy in comparison with steroid therapy alone.ConclusionThe rapid improvement of hypercholesterolemia with LDL-A treatment may provide a new approach for a high rate of improvement in the degree of NS in steroid-resistant NS of FGS and MCNS. The pathogenic role of hyperlipidemia in long-standing nephrotic syndrome (NS) is known to be responsible for both the progression of glomerulosclerosis and tubulointerstitial injury, especially in focal segmental glomerulosclerosis (FGS). Aggressive lipid lowering treatment by low density lipoprotein (LDL) apheresis (LDL-A) using a dextran sulfate cellulose column to treat patients with steroid-resistant or frequently recurrent severe NS was performed first without fixing the protocol in eight patients with FGS and one with minimal change nephrotic syndrome (MCNS). The period of NS before LDL-A, number and average intervals of LDL-A until the end of the therapy, and the prognosis were investigated. Next, a multicenter study with a fixed protocol of LDL-A treatment was designed in combination with steroid therapy for treatment twice a week for three weeks and weekly for six weeks, and was performed in 17 patients with FGS. The effects on the state of NS in addition to the change of urinary eicosanoid metabolites and remission rates were evaluated. In the preliminary study, along with a rapid improvement of hyperlipidemia, a high incidence of remission was achieved by LDL-A performed at relatively short intervals. In the multicenter study with a fixed protocol, there was a significant decrease of urinary protein (P < 0.001) and increase of serum albumin (P < 0.02) as well as a decrease of thromboxane B2 (TXB2) excretion (P < 0.05) after the treatment. Urinary excretion of TXB2 was significantly reduced after LDL-A (P < 0.05). The rate of entering into complete or incomplete remission was 71% with a relatively short duration of nephrotic-range proteinuria using the LDL-A therapy in comparison with steroid therapy alone. The rapid improvement of hypercholesterolemia with LDL-A treatment may provide a new approach for a high rate of improvement in the degree of NS in steroid-resistant NS of FGS and MCNS." @default.
• W2023653902 created "2016-06-24" @default.
• W2023653902 creator A5001403591 @default.
• W2023653902 creator A5002530228 @default.
• W2023653902 creator A5010400481 @default.
• W2023653902 creator A5033364831 @default.
• W2023653902 creator A5041884449 @default.
• W2023653902 creator A5051402210 @default.
• W2023653902 creator A5065387046 @default.
• W2023653902 creator A5066432483 @default.
• W2023653902 creator A5076793591 @default.
• W2023653902 creator A5081749381 @default.
• W2023653902 creator A5082604938 @default.
• W2023653902 creator A5086135295 @default.
• W2023653902 date "1999-07-01" @default.
• W2023653902 modified "2023-10-16" @default.
• W2023653902 title "Low density lipoprotein apheresis therapy for steroid-resistant nephrotic syndrome" @default.
• W2023653902 cites W1983760495 @default.
• W2023653902 cites W1987344094 @default.
• W2023653902 cites W1993531087 @default.
• W2023653902 cites W2030089656 @default.
• W2023653902 cites W2037930690 @default.
• W2023653902 cites W2050705339 @default.
• W2023653902 cites W2059594476 @default.
• W2023653902 cites W2080563483 @default.
• W2023653902 cites W2148473926 @default.
• W2023653902 doi "https://doi.org/10.1046/j.1523-1755.1999.07130.x" @default.
• W2023653902 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/10412754" @default.
• W2023653902 hasPublicationYear "1999" @default.
• W2023653902 type Work @default.
• W2023653902 sameAs 2023653902 @default.
• W2023653902 citedByCount "47" @default.
• W2023653902 countsByYear W20236539022014 @default.
• W2023653902 countsByYear W20236539022015 @default.
• W2023653902 countsByYear W20236539022016 @default.
• W2023653902 countsByYear W20236539022017 @default.
• W2023653902 countsByYear W20236539022018 @default.
• W2023653902 countsByYear W20236539022019 @default.
• W2023653902 countsByYear W20236539022021 @default.
• W2023653902 countsByYear W20236539022023 @default.
• W2023653902 crossrefType "journal-article" @default.
• W2023653902 hasAuthorship W2023653902A5001403591 @default.
• W2023653902 hasAuthorship W2023653902A5002530228 @default.
• W2023653902 hasAuthorship W2023653902A5010400481 @default.
• W2023653902 hasAuthorship W2023653902A5033364831 @default.
• W2023653902 hasAuthorship W2023653902A5041884449 @default.
• W2023653902 hasAuthorship W2023653902A5051402210 @default.
• W2023653902 hasAuthorship W2023653902A5065387046 @default.
• W2023653902 hasAuthorship W2023653902A5066432483 @default.
• W2023653902 hasAuthorship W2023653902A5076793591 @default.
• W2023653902 hasAuthorship W2023653902A5081749381 @default.
• W2023653902 hasAuthorship W2023653902A5082604938 @default.
• W2023653902 hasAuthorship W2023653902A5086135295 @default.
• W2023653902 hasBestOaLocation W20236539021 @default.
• W2023653902 hasConcept C10146269 @default.
• W2023653902 hasConcept C126322002 @default.
• W2023653902 hasConcept C126894567 @default.
• W2023653902 hasConcept C134018914 @default.
• W2023653902 hasConcept C2777390665 @default.
• W2023653902 hasConcept C2778163477 @default.
• W2023653902 hasConcept C2778415529 @default.
• W2023653902 hasConcept C2778930706 @default.
• W2023653902 hasConcept C2779091943 @default.
• W2023653902 hasConcept C2779561371 @default.
• W2023653902 hasConcept C2780091579 @default.
• W2023653902 hasConcept C555293320 @default.
• W2023653902 hasConcept C62746215 @default.
• W2023653902 hasConcept C71924100 @default.
• W2023653902 hasConcept C77411442 @default.
• W2023653902 hasConcept C90924648 @default.
• W2023653902 hasConceptScore W2023653902C10146269 @default.
• W2023653902 hasConceptScore W2023653902C126322002 @default.
• W2023653902 hasConceptScore W2023653902C126894567 @default.
• W2023653902 hasConceptScore W2023653902C134018914 @default.
• W2023653902 hasConceptScore W2023653902C2777390665 @default.
• W2023653902 hasConceptScore W2023653902C2778163477 @default.
• W2023653902 hasConceptScore W2023653902C2778415529 @default.
• W2023653902 hasConceptScore W2023653902C2778930706 @default.
• W2023653902 hasConceptScore W2023653902C2779091943 @default.
• W2023653902 hasConceptScore W2023653902C2779561371 @default.
• W2023653902 hasConceptScore W2023653902C2780091579 @default.
• W2023653902 hasConceptScore W2023653902C555293320 @default.
• W2023653902 hasConceptScore W2023653902C62746215 @default.
• W2023653902 hasConceptScore W2023653902C71924100 @default.
• W2023653902 hasConceptScore W2023653902C77411442 @default.
• W2023653902 hasConceptScore W2023653902C90924648 @default.
• W2023653902 hasLocation W20236539021 @default.
• W2023653902 hasLocation W20236539022 @default.
• W2023653902 hasOpenAccess W2023653902 @default.
• W2023653902 hasPrimaryLocation W20236539021 @default.
• W2023653902 hasRelatedWork W1974727559 @default.
• W2023653902 hasRelatedWork W2054627468 @default.
• W2023653902 hasRelatedWork W2056746202 @default.
• W2023653902 hasRelatedWork W2101825593 @default.
• W2023653902 hasRelatedWork W2399119512 @default.
• W2023653902 hasRelatedWork W2404744687 @default.
• W2023653902 hasRelatedWork W2413760456 @default.
• W2023653902 hasRelatedWork W2418228134 @default.

• next